KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday March 22, 2024, at 12 p.m. ET. The discussion will focus on Cingulate's pipeline and product portfolio, including ...

KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be attending DCAT Week (Drug, Chemical & Associated Technologies Association) March 18-21, 2024, in Midtown Manhattan. Cingulate Chairman and CEO Shane J. Schaffer, and Cingulate COO Laurie A. Myers, wil ...

KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the closing of its public offering of an aggregate of 3,750,000 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase ...

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the pricing of its public offering of an aggregate of 3,750,000 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase ...

As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. 333-276502 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CINGULATE INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 86-3825535 (I.R.S. Employer Identification Number) ...

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn who retired from the company in December. "Today we are pleased to welcome Jennifer Callahan to the C- ...

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Werth Family Investment Associates, LLC ("WFIA"), the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $3.3 million of debt and accrued interest into Cin ...

As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CINGULATE INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 86-3825535 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1901 W. 47th Place Kansas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 As filed with the Securities and Exchange Commission on November 15, 2023 Registration No. 333- REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CINGULATE INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 86-3825535 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1901 W. 47th Place Kansa ...

Cingulate Inc. (Exact name of registrant as specified in its charter) Delaware 86-3825535 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1901 W. 47 Place Kansas City, KS 66205 (Address of principal executive offices) (Zip Code) (913) 942-2300 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | --- | --- | --- | |-------------------------------------------------------------------|-------------- ...